[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"atrial-fibrillation-prevention-of-stroke\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:atrial-fibrillation-prevention-of-stroke":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,51,86,116],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100646829","digital-screening-for-atrial-fibrillation-to-prevent-stroke-100646829",false,"NCT07684053","Digital Screening for Atrial Fibrillation to Prevent Stroke","Digital Screening for Atrial Fibrillation to Prevent Stroke: The Randomized Austrian Digital Heart Study","ADHP","Inclusion Criteria\n\n1. Age ≥ 65 years\n2. Policyholder in Austria (active unique social insurance number)\n3. Written electronic informed consent Exclusion Criteria\n\na) Currently treated with oral anticoagulation b) Cardiac implanted electronic device (CIED)","ALL","65 Years",{"count":20,"type":21},100060,"ESTIMATED","INTERVENTIONAL",[24],"NA","The Austrian Digital Heart Study is a population-based, siteless, randomized, controlled digital trial testing whether a smartphone-based atrial fibrillation screening and management pathway reduces stroke hospitalizations compared with usual care. Adults aged 65 years or older in Austria are randomized to either a digital intervention using the 'Pulskontrolle' app or to usual care. The intervention includes smartphone-camera photoplethysmography for atrial fibrillation screening, confirmatory 7-day ECG patch monitoring in case of suspected atrial fibrillation, and digital education and management support. The primary outcome is hospitalization for stroke of any type within 48 months.",[27,28],"Atrial Fibrillation (Prevention of Stroke)","Stroke",[30,31,32,33,34,35,36,37,38],"Digital Health","Atrial Fibrillation Screening","Photoplethysmography","Smartphone","ECG Patch","Stroke Prevention","Randomized Controlled Trial","Siteless Trial","Telehealth","RECRUITING","2026-06-29",{"date":42,"type":43},"2026-07-06","ACTUAL",{"date":40,"type":21},{"date":46,"type":21},"2032-06-01",{"name":48,"class":49},"Medical University Innsbruck","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":62,"conditions":63,"keywords":67,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":50},"100637216","pharmacy-based-opportunistic-atrial-fibrillation-screening-integrated-with-emergency-services-numaplus-fa-100637216","NCT07598903","Pharmacy-based Opportunistic Atrial Fibrillation Screening Integrated With Emergency Services (NUMAPLUS-FA)","Pharmacy-based Opportunistic Screening for Atrial Fibrillation Using a Portable ECG Device Integrated With Emergency Medical Services: a Prospective Type-1 Hybrid Implementation Study (NUMAPLUS Project)","Numaplus_FA","Inclusion Criteria:\n\n1. Age 65 years or older\n2. Attending a participating community pharmacy for any routine healthcare purpose\n3. No prior documented or patient-reported diagnosis of atrial fibrillation\n4. Capacity to provide written informed consent\n\nExclusion Criteria:\n\n1. Confirmed prior diagnosis of atrial fibrillation\n2. Implanted pacemaker, implantable cardioverter-defibrillator (ICD) or other intracardiac device\n3. Clinically evident haemodynamic instability requiring direct emergency 061 activation (active chest pain, severe dyspnoea, syncope)\n4. Concurrent participation in another cardiac rhythm monitoring study\n5. Inability to maintain the required position for a 30-second ECG recording",{"count":60,"type":21},380,[24],"This study evaluates the feasibility and fidelity of an opportunistic atrial fibrillation (AF) screening programme conducted in 38 community pharmacies in Seville (Spain), using the Kardias® 6-lead portable ECG device, coordinated with the emergency medical services centre Salud Responde (CES 061) and primary care physicians. Eligible participants are individuals aged 65 years or older without a prior AF diagnosis who attend a participating pharmacy for any routine purpose. The screening consists of a 30-second ECG recording performed by a trained community pharmacist. Positive or indeterminate results are transmitted in real time to Salud Responde for clinical validation and referral to primary care. The study is evaluated using the RE-AIM framework (Reach, Effectiveness, Adoption, Implementation, Maintenance). The primary outcome is protocol fidelity, measured by the Implementation Adherence Grade (IAG). The study is part of the NUMAPLUS project, funded by INTERREG VI-A España-Portugal (POCTEP 2021-2027), co-financed by the European Regional Development Fund (ERDF).",[27,64,65,66],"Arrythmia, Cardiac","Mass Screening","Pharmacies",[68,69,70,71,72,73,74,75],"atrial fibrillation","opportunistic screening","community pharmacy","RE-AIM","implementation science","emergency medical services","portable ECG","hybrid implementation study","NOT_YET_RECRUITING","2026-05-20",{"date":79,"type":43},"2026-05-22",{"date":81,"type":21},"2026-06-01",{"date":83,"type":21},"2026-12-31",{"name":85,"class":49},"Centro de Emergencias Sanitarias 061 Andalucía",{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":17,"minAge":93,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":22,"phases":96,"briefSummary":97,"conditions":98,"keywords":103,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":50},"100624296","the-southern-norway-post-stroke-atrial-fibrillation-study-100624296","NCT07407790","The Southern-Norway Post-Stroke Atrial Fibrillation Study","SNAPS","Inclusion Criteria:\n\n* Patients hospitalized with an ischemic stroke or transient ischemic attack (TIA), including amaurosis fugax, occurring within the last 2 weeks.\n* Initial evaluation of CT and\u002For CT angiography and\u002For MRI supports a diagnosis of TIA or ischemic stroke.\n* Available smartphone and access to the ECG247-app to be able to participate in the study.\n* Estimated life span of \\>6 month\n* Permanent address in Norway\n* Informed Consent, Capable of giving signed informed consent or consent through proxy as described in Appendix which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the study protocol.\n\nExclusion Criteria:\n\nParticipants are excluded from the study if any of the following criteria apply:\n\nMedical Conditions\n\n* Known AF or atrial flutter prior to inclusion\n* Concomitant use of anticoagulation therapy or established contraindication to its use. To date this includes apixaban, rivaroxaban, edoxaban, dabigatran, warfarin and indirect thrombin inhibitors (except for short term thrombosis prevention).\n* Implanted pacemaker, ICD or loop-recorder\n* \\>70% stenosis of carotid artery on ipsilateral side to the stroke on CT angiography or ultrasound\n* Pregnancy","18 Years",{"count":95,"type":21},450,[24],"This study evaluates whether a procedure using a new wireless heart sensor patch is equal to or better than the standard hospital procedures and equipment at detecting an irregular heartbeat called Atrial Fibrillation (AF) after an ischemic stroke. Atrial fibrillation is a major cause of stroke, but it can be difficult to catch because it often comes and goes.\n\nThe study will include approximately 450 adults who have had a stroke or a transient \"mini-stroke\" (TIA) within the last two weeks. Participants will be assigned by chance (randomized) to one of two groups:\n\n* Group 1 (Intervention): Participants wear the \"ECG247 Smart Heart Sensor.\" This is a small patch that sticks to the chest and connects to a smartphone. It is worn continuously for up to 14 days, even after leaving the hospital.\n* Group 2 (Standard Care): Participants receive the standard hospital check-up. This typically involves using a \"Holter monitor\" (a device with wires and electrodes) for a period of about 24 to 48 hours some time after leaving the hospital.\n\nThe main goal is to see if the procedure using the patch is equal to the standard procedure in detecting atrial fibrillation in participants. The study will also measure how quickly doctors can start the correct medication and how easy the patients find the devices to use.",[99,27,100,101,102],"Atrial Fibrillation (AF)","Ischemic Stroke","Secondary Prevention","Arrhythmia Atrial",[104,68,105],"stroke","anticoagulation","2026-02-05",{"date":108,"type":43},"2026-02-12",{"date":110,"type":43},"2026-01-10",{"date":112,"type":21},"2029-12",{"name":114,"class":115},"Sorlandet Hospital HF","OTHER_GOV",{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":17,"minAge":93,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":126,"phases":4,"briefSummary":127,"conditions":128,"keywords":133,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":50},"100589046","stroke-risk-assessment-and-markers-of-blood-clotting-in-patients-with-newly-diagnosed-non-valvular-atrial-fibrillation-nvaf-who-have-not-received-oral-anticoagulation-therapy-oac-therapy-prior-to-inclusion-100589046","NCT06949319","Stroke Risk Assessment and Markers of Blood Clotting in Patients With Newly Diagnosed Non-valvular Atrial Fibrillation (NVAF), Who Have Not Received Oral Anticoagulation Therapy (OAC-therapy) Prior to Inclusion","Individualized Stroke Risk Scores and Hemostatic Profile in Oral Anticoagulant-naïve (OAC-naïve) Patients With Non-valvular Atrial Fibrillation (NVAF)","BIO-AF","Inclusion Criteria:\n\n* Patients with newly diagnosed non-valvular atrial fibrillation (NVAF), who are oral anticoagulant-naïve (OAC-naïve) prior to inclusion.\n* Age ≥ 18 years.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Ongoing OAC treatment prior to inclusion.\n* Valvular AF (mechanical heart valves or moderate-severe mitral stenosis).\n* Secondary AF due to an acute reversible precipitant (e.g., infection, surgery, thyrotoxicosis, etc.).\n* Pregnant or breastfeeding women.\n* Treatment with oral contraceptives.\n* End-stage renal disease (creatinine clearance \\\u003C15 mL\u002Fmin as calculated by the Cockcroft-Gault equation).\n* Connective tissue diseases.\n* Active cancer (cancer diagnosis not followed by curative procedures six months from the date of diagnosis).\n* Major surgery (\\\u003C three months).\n* Acute coronary syndrome, stroke\u002FTIA, and venous thromboembolism within three months prior to inclusion.\n* Thrombophilia.\n* Significant liver disease.\n* Significant hematological disease.",{"count":125,"type":21},150,"OBSERVATIONAL","Background:\n\nAtrial fibrillation (AF) is the most common heart rhythm disorder worldwide. Globally, there are 37.5 million people with AF. AF increases the risk of death, heart failure, and stroke, which severely affect patients and also lead to high healthcare costs. Around 25% of all strokes are caused by AF, and patients with stroke due to AF tend to have a higher risk of death and more disability compared to stroke patients without AF.\n\nStroke prevention is, therefore, an important part of AF treatment, in which blood thinning medication has an important role. However, blood thinners increase the risk of bleeding. Therefore, it is important to divide patients with AF into different risk groups, known as risk assessment, to figure out who will benefit the most from blood thinners. To be able to divide patients into different risk groups, various stroke risk assessment tools have been developed, such as the CHA2DS2-VASc score and the ABC-stroke score. The most commonly used tool is the CHA2DS2-VASc score, including only clinical risk factors, such as high blood pressure, diabetes, etc. The ABC-stroke score, which includes blood markers of heart function, has been proven to outperform the CHA2DS2-VASc score in terms of predicting stroke in AF patients. However, the CHA2DS2-VASc score remains the primary stroke risk assessment tool for AF patients in current guidelines.\n\nAfter looking at the different risk factors, patients are divided into three groups: low, intermediate, and high risk. High-risk patients must take blood-thinning medication for life, while low-risk patients do not need it. In the medium-risk group, it remains uncertain whether blood thinners should be given or not.\n\nDespite the broad use of the CHA2DS2-VASc score, the score itself has limitations. The score does not include important factors, such as the duration of AF, the size and function of the upper heart chambers, as well as the stiffness of the heart, and markers of blood clotting, which are proven markers of a state that inceases the risk of blood clots. Furthermore, the CHA2DS2-VASc score does not consider whether heart failure, high blood pressure, and diabetes are well-controlled or not, which could lead to overuse of blood thinners. Therefore, the current risk assessment tools for patients with AF are incomplete, and improvements are needed.\n\nOverall hypothesis:\n\nOverall hypothesis is that the different components of the CHA2DS2-VASc score and ABC-stroke score affect blood clotting markers differently, depending on whether conditions like heart failure, high blood pressure, and diabetes (modifiable risk factors) are well-controlled or not. Investigators also expect to see differences in blood clotting markers across different stroke risk groups (low, intermediate, and high risk, based on the CHA2DS2-VASc score and ABC-stroke score) in AF patients who have not yet started blood thinning medication. Furthermore, investigators believe that the duration of AF, the size\u002Ffunction of the upper heart chambers, as well as the stiffness of the heart, can reflect an increased risk of blood clots in AF patients.\n\nOverall goal of the study:\n\nThe overall goal of the study is to help improve the current tools used to assess the risk of stroke in patients with newly diagnosed AF. This will be done by adding more factors to the current risk assessment tools that reflect an increased risk of stroke, such as the burden of AF, the size\u002Ffunction of the heart's upper chambers, as well as the stiffness of the heart, and using biomarkers that show the blood's ability to clot as a substitute measure for stroke risk.\n\nMethods:\n\nThe study is a cross-sectional, single-center observational study and will take place at Esbjerg Hospital - University Hospital of Southern Denmark, involving collaboration between the Unit for Thrombosis Research, Department of Clinical Diagnostics and the Department of Cardiology.\n\nThe study population will consist of 150 participants with newly diagnosed AF. The participants must not be taking a specific type of blood thinner, called anticoagulant therapy (OAC-therapy), before being included in the study. The participants will be recruited with the help of the general practitioners (GPs). The general practitioners will be thoroughly informed about the study and the importance of waiting to start OAC-therapy until the participants have been seen at the cardiology outpatient clinic. The participants will be scheduled for a blood test, an ultrasound of the heart (echocardiography), and a 7-day heart rhythm monitoring within 4 days after their first meeting with the GP.",[99,27,129,130,131,28,132],"Atrial Fibrillation New Onset","Non Valvular Atrial Fibrillation","Stroke (in Patients With Atrial Fibrillation)","Thrombosis",[134,135,136,137,138,139,140,141,142,143,144,28,145,146],"Stroke risk assessment in patients with atrial fibrillation","OAC-naïve patients with newly diagnosed atrial fibrillation","Hemostatic biomarkers","CHA2DS2-VASc score","ABC-stroke score","AF-burden","Left Atrial Function Index (LAFI)","Echocardiography","HFA-PEFF score","H2FPEF score","Heart failure with preserved ejection fraction (HFpEF)","Oral anticoagulant therapy","Non-valvular atrial fibrillation","2025-04-21",{"date":149,"type":43},"2025-04-29",{"date":151,"type":43},"2024-08-16",{"date":153,"type":21},"2025-09",{"name":155,"class":49},"Nedim Tojaga"]